

## SUMMARY OF PRODUCT CHARACTERISTICS

### 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Ovidrench S & C 10% w/v Oral Suspension for Cattle and Sheep

### 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

<b>Active substance:</b>	<b>per ml</b>
Albendazole	100 mg
<b>Other Relevant Constituents:</b>	
Selenium (as sodium selenite)	1.08 mg
Cobalt (as cobalt sulfate)	2.5 mg
<b>Excipients:</b>	
Methyl Parahydroxybenzoate (E218) (preservative)	2 mg
Propyl Parahydroxybenzoate (E216) (preservative)	0.2 mg
Acid Brilliant Green BS (E142) (colouring agent)	0.015 mg

For a full list of excipients, see section 6.1

### 3. PHARMACEUTICAL FORM

Oral suspension  
Pale blue

### 4. CLINICAL PARTICULARS

#### 4.1. Target species

Cattle and sheep.

#### 4.2. Indications for use, specifying the target species

A broad spectrum multi-purpose anthelmintic for the control of mature and developing, immature forms of gastrointestinal roundworms, lungworms, tapeworms and adult liver fluke in cattle and sheep. The product is also ovicidal against fluke and roundworm eggs.

#### **In Cattle**

It is active against the following species:

Roundworms: *Teladorsagia*, *Haemonchus*, *Trichostrongylus*, *Nematodirus*, *Oesophagostomum*, *Bunostomum*, *Cooperia* and *Strongyloides* spp. It is usually effective against inhibited larvae of *Cooperia* and *Teladorsagia*.

Lungworms: *Dictyocaulus viviparus*.

Tapeworms: *Moniezia* spp.

Adult liver fluke: *Fasciola hepatica*.

The product is ovicidal and will kill fluke and roundworm eggs, thus reducing pasture contamination.

**In Sheep**

It is active against benzimidazole-susceptible strains of the following species:

Roundworms: *Teladorsagia*, *Haemonchus*, *Trichostrongylus*, *Nematodirus* (including *N. battus*), *Chabertia* and *Oesophagostomum*. It is usually effective against inhibited larvae of *Teladorsagia*.

Lungworms: *Dictyocaulus filaria*.

Tapeworms: *Moniezia* spp.

Adult liver fluke: *Fasciola hepatica*.

The product is ovicidal and will kill fluke and roundworm eggs, thus reducing pasture contamination.

**4.3. Contraindications**

Do not use in animals with known hypersensitivity to the active ingredient.

**4.4. Special warnings for each target species**

Cattle suffering from severe lung damage due to heavy lungworm infestation may continue to cough for some weeks after dosing.

Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy:

- Too frequent and repeated use of anthelmintics from the same class, over an extended period of time.
- Underdosing, which may be due to underestimation of body weight, misadministration of the product, or lack of calibration of the dosing device (if any).

Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests (e.g. Faecal Egg Count Reduction Test). Where the results of the test(s) strongly suggest resistance to a particular anthelmintic, an anthelmintic belonging to another pharmacological class and having a different mode of action should be used.

Resistance to benzimidazoles (which includes albendazole) has been reported in *Teladorsagia*, *Haemonchus*, *Cooperia* and *Trichostrongylus* species in small ruminants in a number of countries, including the EU. Resistance to albendazole has been reported in *Cooperia* and *Teladorsagia* species in cattle in developed countries such as in New Zealand. Therefore the use of this

product should be based on local (regional, farm) epidemiological information about susceptibility of nematodes and recommendations on how to limit further selection for resistance to anthelmintics.

To reduce this risk, dosing programmes should be discussed with a veterinary surgeon.

#### **4.5. Special precautions for use**

Avoid the introduction of contamination during use.

The product should only be used in areas where deficiencies of cobalt and selenium are likely to occur. If in any doubt, seek the advice of a veterinary surgeon.

i) Special precautions for use in animals

Care must be taken not to damage the pharyngeal region when dosing, particularly in sheep.

Do not administer other cobalt and selenium supplements concurrently unless specifically advised by your vet. Not to be diluted.

ii) Special precautions to be taken by the person administering the veterinary medicinal product to animals

Avoid direct contact with the product.

Wear suitable protective clothing including impermeable rubber gloves. In the event of accidental eye exposure, flush eye thoroughly with running water. If irritation persists, seek medical attention. In the event of accidental skin exposure, wash the affected areas with soap and water. If irritation persists, seek medical attention. Wash hands after use.

#### **4.6. Adverse reactions (frequency and seriousness)**

None known.

#### **4.7. Use during pregnancy, lactation or lay**

The use of the product in breeding bulls or pregnant cattle is not expected to interfere with their reproductive performance.

Do not dose ewes at the 'fluke and worm' dose rate (7.5 mg/kg), during tugging or for 1 month after removing the rams.

Ovispec S&C 10 % w/v can be safely used during lactation.

#### 4.8. Interaction with other medicinal products and other forms of interaction

Administration of ionophores to lambs has been shown to enhance selenium bioavailability. Concurrent administration of ionophores and the product may therefore lead to an increased risk of selenium toxicity.

#### 4.9. Amounts to be administered and administration route

For oral administration only using properly calibrated dosing equipment. To ensure administration of a correct dose, body weight should be determined as accurately as possible; accuracy of the dosing device should be checked.

Shake the container before use.

Do not mix with other products.

##### **Cattle:**

###### Worm dose

For the control of roundworms, lungworms, tapeworms and fluke and roundworm eggs.

Dosage: 7.5 mg albendazole per kg bodyweight (0.075 ml/kg bodyweight).

###### Fluke and worm dose

For the additional treatment of adult liver fluke (chronic fascioliasis) in cattle.

Dosage: 10 mg albendazole per kg bodyweight (0.1 ml/kg bodyweight).

##### **Sheep:**

###### Worm Dose

For the control of roundworms, lungworms, tapeworms and fluke and roundworm eggs.

Dosage: 5 mg albendazole per kg bodyweight (0.05 ml/kg bodyweight).

###### Fluke and Worm Dose

For the additional treatment of adult liver fluke (chronic fascioliasis) in sheep.

Dosage: 7.5 mg albendazole per kg bodyweight (0.075 ml/kg bodyweight).

Administration with a suitable drenching gun is recommended (see 4.5).

#### 4.10. Overdose (symptoms, emergency procedures, antidotes), if necessary

Benzimidazoles have a wide safety margin.

#### 4.11. Withdrawal periods

##### **Cattle:**

Meat: 14 days

Milk: 60 hours

##### **Sheep:**

Meat: 4 days

Milk: Do not use in sheep producing milk for human consumption.

## 5. PHARMACOLOGICAL PROPERTIES

**ATCVet Code:** QP52AC11

### 5.1. Pharmacodynamic properties

A broad spectrum multi-purpose anthelmintic for the control of mature and developing immature forms of gastrointestinal roundworms, lungworms, tapeworms and adult liver fluke in cattle and sheep. The product is also ovicidal against fluke and roundworm eggs.

Albendazole belongs to the benzimidazole class of anthelmintics.

Benzimidazoles bind to nematode tubulin, a protein necessary for the formation and viability of microtubules. This occurs primarily in absorptive intestinal cells resulting in the absence of microtubules in the intestinal cells of the nematode, with the result that these cells cannot absorb nutrients, thus causing a consequent reduction in glycogen and effective starvation of the parasites. Structural differences have been shown to exist between tubulin from mammalian and helminth sources, resulting in the preferential toxicity of albendazole to the helminth and not to the host. Benzimidazoles have also been shown to inhibit the fumarate reductase system of helminths and impair energy production.

The selenium and cobalt are trace elements of use as nutritional supplements and are not intended to be used therapeutically. Administration of ionophores to lambs have been shown to enhance selenium bioavailability. Concurrent administration of ionophores and Ovispec S&C 10 % w/v may therefore lead to an increased risk of selenium toxicity.

Anthelmintic Class: 1-BZ

### 5.2. Pharmacokinetic particulars

None stated

## 6. PHARMACEUTICAL PARTICULARS

### 6.1. List of excipients

Acid Brilliant Green BS (E142)  
Methyl Parahydroxy benzoate (E218)  
Propyl Parahydroxy benzoate (E216)  
Sodium selenite  
Cobalt sulfate  
Citric Acid Monohydrate  
Sodium Citrate Dihydrate  
Xanthan Gum  
Povidone  
Polysorbate 20  
Propylene Glycol

Simethicone Emulsion  
Purified Water

## **6.2. Incompatibilities**

None known

## **6.3. Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 18 months

## **6.4. Special precautions for storage**

Do not store above 25 °C.

## **6.5. Nature and composition of immediate packaging**

1.0, 2.5 and 5.0 litre white high density polyethylene back pack with white high density polyethylene cap (screw fit).

10.0 litres high density polyethylene jerricans with white high density polyethylene cap (screw fit) with induction reseal liner.

Not all pack sizes may be marketed.

## **6.6. Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products**

DANGEROUS to fish and aquatic life.

Do not contaminate ponds, waterways or ditches with the product or used containers.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

## **7. MARKETING AUTHORISATION HOLDER**

Bimeda Animal Health Limited  
2 / 3 / 4 Airton Close  
Tallaght  
Dublin 24  
Ireland

## **8. MARKETING AUTHORISATION NUMBER**

Vm 50146/4032

## **9. DATE OF FIRST AUTHORISATION**

17 December 2001

**10. DATE OF REVISION OF THE TEXT**

October 2018

Approved: 25 October 2018

A handwritten signature in black ink, appearing to read "D. Austin", with a horizontal line extending to the right.